Document is current
Any future updates will be listed below
-
Authors
Nasser, Mouhamad https://orcid.org/0000-0001-8373-8032
Larrieu, Sophie
Boussel, Loic
Si-Mohamed, Salim
Bazin, Fabienne
Marque, Sébastien
Massol, Jacques
Thivolet-Bejui, Françoise
Chalabreysse, Lara
Maucort-Boulch, Delphine
Hachulla, Eric
Jouneau, Stéphane
Le Lay, Katell
Cottin, Vincent https://orcid.org/0000-0002-5591-0955
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03858842 at ClinicalTrials.govDocuments that mention this clinical trial
Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)
https://doi.org/10.1186/s12931-021-01749-1
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
- License Information
-
More Information
Article History
Received: 25 February 2021
Accepted: 17 May 2021
First Online: 24 May 2021
Declarations
:
: This study was conducted as part of the wider PROGRESS portfolio under Reference Methodology (MR) 004 following approval by the Comité d’Expertise pour les Recherches, les Etudes et les Evaluations dans le domaine de la Santé (CEREES) on 18 August 2018 (TPS 72584) and by the Commission Nationale de l'Informatique et des Libertés (CNIL) on 9 November 2018 (918305).
: Not applicable.
: MN reports non-financial support from F. Hoffmann-La Roche, Actelion, AstraZeneca, Chiesi, and Boehringer Ingelheim outside the submitted work. JM reports personal fees from Boehringer Ingelheim during the conduct of the study, research and paid consultancy for Boehringer Ingelheim outside the submitted work, and personal fees from RaDiCo Cohorts (INSERM). DM-B reports personal fees from MaatParma, outside the submitted work. EH reports consulting fees/meeting fees from Actelion, Boehringer Ingelheim, Bayer, GSK, Roche-Chugai, Sanofi-Genzyme; speaking fees from Actelion, GSK, Roche-Chugai; and research funding from Octapharma, CSL Behring, GSK, Roche-Chugai and Actelion. SJ has received fees, funding or reimbursement for national and international conferences, boards, expert or opinion groups, research projects over the past 5 years from Actelion, AIRB, AstraZeneca, Bellorophon Therapeutics, Biogen, BMS, Boehringer Ingelheim, Chiesi, Fibrogen, Galecto Biotech, Genzyme, Gilead, GSK, LVL, Mundipharma, Novartis, Olam Pharm, Pfizer, Pliant Therapeutics, Roche, Sanofi and Savara-Serendex. KLL was an employee of Boehringer Ingelheim France at the time of the research presented in this manuscript. VC reports personal fees and non-financial support from Actelion, Bayer/MSD, and Roche, grants, personal fees, and non-financial support from Boehringer Ingelheim, personal fees from Novartis, Sanofi, Celgene, Galapagos, Galecto and Shionogi, outside the submitted work. SL, LB, SS-M, FB, SM, FTB and LC do not have any disclosures.
